Crispr Therapeutics AG (NASDAQ:CRSP) – Research analysts at Piper Jaffray Companies raised their Q1 2020 earnings estimates for shares of Crispr Therapeutics in a research note issued on Tuesday, November 26th. Piper Jaffray Companies analyst E. Tenthoff now forecasts that the company will post earnings per share of ($1.20) for the quarter, up from their prior forecast of ($1.29). Piper Jaffray Companies has a “Buy” rating and a $104.00 price target on the stock. Piper Jaffray Companies also issued estimates for Crispr Therapeutics’ Q2 2020 earnings at ($1.30) EPS, Q3 2020 earnings at ($1.39) EPS, Q4 2020 earnings at ($1.49) EPS, FY2020 earnings at ($5.38) EPS, Q1 2021 earnings at ($1.65) EPS, Q2 2021 earnings at ($1.81) EPS, Q3 2021 earnings at ($1.88) EPS and FY2021 earnings at ($7.38) EPS.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million.
CRSP has been the subject of a number of other reports. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Jefferies Financial Group started coverage on shares of Crispr Therapeutics in a research report on Thursday, August 1st. They set a “buy” rating and a $64.00 price objective for the company. ValuEngine raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Finally, BidaskClub raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $69.54.
NASDAQ:CRSP opened at $68.11 on Thursday. Crispr Therapeutics has a 1-year low of $22.22 and a 1-year high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $49.29 and a 200 day simple moving average of $46.08. The stock has a market capitalization of $3.63 billion, a PE ratio of -19.80 and a beta of 3.15.
In other news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $390,000. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the company. Benjamin Edwards Inc. boosted its position in shares of Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares during the period. NEXT Financial Group Inc boosted its position in shares of Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after acquiring an additional 549 shares during the period. US Bancorp DE boosted its position in shares of Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after acquiring an additional 526 shares during the period. Coastal Investment Advisors Inc. bought a new stake in shares of Crispr Therapeutics in the third quarter valued at about $26,000. Finally, BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics in the second quarter valued at about $39,000. 49.81% of the stock is owned by institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: What is the Hang Seng index?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.